Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory


  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population

    Minority communities unspecified

  • Occupations of Interest



Project Summary The continuing prevalence of SARS-CoV-2 coronavirus cases has led to an urgent need to developstrategies for identifying patients who are likely to have mild vs. severe disease to optimally allocate healthcare resources. It is also critical that we understand why certain patients develop severe disease. One possiblemechanism is through antibody-dependent enhancement (ADE) a phenomenon well documented for otherviruses including SARS. In order to develop safe and effective vaccines, it is essential that we determinewhether the humoral immune response to Covid-19 induces antibodies that can mediate ADE and tounderstand which aspects of the immune response to the virus correlate with good clinical outcomes.Addressing this knowledge gap quickly is necessary to inform vaccine trials, which are already underway orare about to start. Our multidisciplinary team has the expertise to address the issues described above. As an independentnon-profit research institution, we are nimble and responsive to evolving health needs. Besides studying aspectrum of patients from across Oklahoma, we are uniquely positioned to look at the consequences of SARS-CoV-2 infection for Native Americans. Native Americans have the shortest life expectancy of any ethnic groupin the US with higher rates of nearly every co-morbidity associated with higher mortality with SARS-CoV-2infection (obesity, diabetes, heart disease, and hypertension). Oklahoma is home to 39 federally recognizedtribes and has the 2nd highest number of American Indians (482,760 according to the 2010 census, and highestpercentage, >10%) in the US. Through our Oklahoma Shared Clinical and Translational Resources (OSCTR),we have partnerships with 5 major tribes, urban Indian clinics and the Southern Plains Tribal Health Boardrepresenting all tribes in Oklahoma, Texas and Kansas. Through these and other interactions, we have strongties to obtain samples from Native Americans with SARS-CoV-2 infection and exposure.Specific Aims1. Identify biomarkers and mechanisms of severe Covid-19 disease pathogenesis2. Characterize the humoral immune response to SARS-CoV-2 infection3. Characterize the T cell immune response to SARS-CoV-2 infectionWhenever feasible, we will compare the responses of Native Americans to those of European Americans todetermine whether Native Americans experience worse outcomes to SARS-CoV-2 infection and if so, whichparts of the immune response is/are suboptimal. We will also compare the responses of individuals with mildvs. severe disease. The knowledge gained should lead to better care for individuals with Covid-19 disease.